Core Viewpoint - The public fund industry achieved impressive performance in Q1 2025, driven by a structural market led by AI and robotics themes [1][2]. Group 1: Fund Performance - The fund performance leaderboard for Q1 2025 was dominated by robotics-themed funds, Beijing Stock Exchange funds, and Hong Kong stock funds [2]. - The top-performing fund, Penghua Carbon Neutral Theme A, managed by Yan Siqian, achieved a return of 60.26%, heavily investing in several robotics stocks [3][5]. - Other notable funds include Ping An Advanced Manufacturing Theme A and Yongying Advanced Manufacturing Smart Selection A, both exceeding 50% returns, also focusing on robotics [6]. Group 2: Robotics Theme Funds - Penghua Carbon Neutral Theme A's significant holdings included stocks like Beite Technology and Hechuan Technology, with Double Forest Co. seeing a year-to-date increase of 118.16% [3][6]. - Fund managers expressed optimism about the rapid production of humanoid robots and the investment opportunities in new materials and technologies [7]. - The focus on core components and AI perception in humanoid robots indicates a growing market potential, with significant room for technological advancement [7][8]. Group 3: Beijing Stock Exchange Funds - Beijing Stock Exchange funds also performed well, with notable returns from funds like CITIC Construction Investment and Huaxia, achieving returns of 38.98% and 37.45% respectively [9]. - These funds have successfully identified high-performing stocks within the Beijing Stock Exchange, such as Kelaite, which saw a remarkable increase of 136.01% [9]. Group 4: Hong Kong Stock Funds - Hong Kong stock funds regained attention, with funds like Huatai Hong Kong Advantage Selection and Zhongyin Hong Kong Medical achieving returns of 38.9% and 32.25% respectively [12]. - The performance of these funds was bolstered by significant gains in pharmaceutical stocks, with companies like Kelun Pharmaceutical and Rongchang Biological seeing increases of 78.08% and 64.58% [12]. - The manager of Huatai Hong Kong Advantage Selection highlighted the growing competitiveness of Chinese innovative drugs in the global market, projecting a significant increase in overseas licensing deals [12][13].

看不懂的 再去读一遍 美股？港股？ 此文值万金 ...

☎️ 联系我们TELEGRAM：https://t.me/YWFHBtiget_bot 🎫加入会员（务必请用Chrome浏览器打开）：https://www.youtube.com/channel/UCxzPFSh9SiT1SvJkS_HkklA/join 影片内容全是吹牛，不构成任何投资建议 🔵 加密交易所 🏦Binance：C2C出入金必备，减免手续费10% 邀请链接： https://accounts.marketwebb.me/register?ref=S4LM4J51 🏦Pionex派网：最好用的网格机器人，减免手续费10% 邀请链接：https://www.pionex.com/zh-TW/signUp?r=0c2hW9qQR8T 🏦OKX欧易：你的链上入口，减免手续费10% https://www.okx.com/join/YWFH666 🏦Bitunix 衍生品赛道成长最快的交易所，免KYC，注册就送5USDT，入金最高送400U 注册链接：https://www.bitunix.com/register?vipCode=YWFH 🏦Bitget交易所注册邀请链接，用我们的邀请码注册减免20% ...